grant
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
Organization UNIVERSITY OF TX MD ANDERSON CAN CTRLocation HOUSTON, UNITED STATESPosted 21 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AddressAndrogenic AgentsAndrogenic CompoundsAndrogensAntibodiesAntitumor ResponseArginineArginine deiminaseArgininosuccinate SynthetaseBiological MarkersBiopsyBlood SerumBody TissuesCBDCACD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancer BiologyCancersCarboplatinCarboplatinoCell BodyCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCell modelCellsCellular FunctionCellular PhysiologyCellular ProcessCellular modelCitrullineClinical DataClinical ResearchClinical StudyClinical TrialsCombination Drug TherapyCombined Modality TherapyCytotoxic ChemotherapyCytotoxic TherapyDataDevelopmentDiseaseDisorderDoseElementsEndogenous Nitrate VasodilatorEndothelium-Derived Nitric OxideEnzyme GeneEnzymesEpitheliumEvaluationGoalsHumanImmuneImmune systemImmunesImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImmunologyImmunomodulationIntermediary MetabolismIntracellular Communication and SignalingIonsL-ArginineMaintenanceMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMass ChromatographyMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasuresMediatingMetabolic PathwayMetabolic ProcessesMetabolismMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModern ManMononitrogen MonoxideMultimodal TherapyMultimodal TreatmentMurineMusNeoplasm MetastasisNitric OxideNitrogen MonoxideNitrogen ProtoxideOutcomePARP InhibitorPARP-1 inhibitorPARPiPD-1 antibodyPD1 antibodyParticipantPathway interactionsPatientsPhagocytosisPhasePhase 1/2 trialPhase I/II TrialPhenotypePlatinumPlatinum BlackPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPolyamine CompoundPolyaminesPolychemotherapyPopulationPositionPositioning AttributePre-Clinical ModelPreclinical ModelsPreclinical dataPrognosisProstate CAProstate CancerProstate malignancyProteinsPt elementReportingRoleSafetySamplingSecondary NeoplasmSecondary TumorSeriesSerumSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSignaling MoleculeSpinal ColumnSpineSubcellular ProcessSubjects SelectionsT cell infiltrationT8 CellsT8 LymphocytesTechnologyTeff cellTherapeutic AndrogenTimeTissuesTumor-associated macrophagesVariantVariationVertebral columnVirulenceaPD-1aPD1advanced prostate cancerandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate canceranti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor responseantiPD-1arginine converting enzymearginine dihydrolasearginine iminohydrolaseargininosuccinate synthasearginosuccinate synthasebackbonebio-markersbiologic markerbiological signal transductionbiomarkerbiomarker identificationcancer cell metabolismcancer metabolismcancer metastasiscancer microenvironmentcastration resistant CaPcastration resistant PCacastration resistant prostate cancerchemotherapycombination chemotherapycombination pharmacotherapycombination therapycombined modality treatmentcombined treatmentdevelopmentaldigitaleffective therapyeffective treatmenteffector T cellendothelial cell derived relaxing factorexperimentexperimental researchexperimental studyexperimentsextracellularhormone refractory prostate canceridentification of biomarkersidentification of new biomarkersimmune microenvironmentimmune modulationimmune regulationimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimprovedinhibitormalignancymarker identificationmenmouse modelmulti-modal therapymulti-modal treatmentmurine modelneoplasm/cancerpathwayperipheral bloodpre-clinical studypreclinical findingspreclinical informationpreclinical studyprospectiveprostate cancer cellprostate cancer cell lineprostate cancer resistant to androgenprostate tumor cellresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolesynergismtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttaxanetreatment effecttrial designtumortumor cell metabolismtumor cell metastasistumor immune microenvironmenttumor metabolismtumor microenvironmenttumor-immune system interactionsαPD-1αPD1
Description preview
PROJECT SUMMARY/ABSTRACT
Androgen indifferent prostate cancers account for a large proportion of the disease lethality and have
limited therapy options, partly due to the lack of identifying biomarkers. To address the unmet need of
developing effective therapies for this subset, we defined the aggressive variant prostate cancers (AVPC)
criteria.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click